DE3: Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction

Sponsor
University of British Columbia (Other)
Overall Status
Completed
CT.gov ID
NCT02017431
Collaborator
(none)
13
1
4
39
0.3

Study Details

Study Description

Brief Summary

The study probes the effects of combined exposures to diesel exhaust and allergens on lung function and on the immune system, specifically focusing on the ability of a particle depletion technique to attenuate effects we and others have seen previously. Individuals are exposed to either filtered air (FA), carefully controlled levels of diesel exhaust (DE) or particle-depleted diesel exhaust (PDDE) in our exposure chamber, after which the investigators will administer an inhaled allergen challenge. 48h later, a procedure called bronchoscopy is used to collect samples from the lungs. After 1 month, the entire procedure is to be repeated with one of the alternate exposures. This will be repeated 4 times (4 exposures; 2 filtered air, 1 diesel exhaust, 1 particle-depleted diesel exhaust)

Condition or Disease Intervention/Treatment Phase
  • Other: Allergen
  • Other: Saline
  • Other: Particle depleted diesel exhaust
N/A

Detailed Description

  1. Purpose/Objective:

The aim of this study is to investigate the ability of depletion of diesel exhaust particles to attenuate adverse effects of diesel exhaust on lung function and on allergic responses.

  1. Hypotheses:

Hypothesis 1: Allergen-specific immune response (specific IgG4, etc; relevant responses in DNA methylation and proteomics) in allergen-challenged airways in sensitized individuals is increased by diesel exhaust "synergy".

Hypothesis 2: Synergistic responses will be greater in asthmatics than in non-asthmatics.

Hypotheses 3: Synergy is attributable to the particulate fraction of DE (i.e. is normalized by particle depletion).

  1. Justification:

Diesel exhaust consists of both gaseous and particulate air pollutants. In recent studies, cardiovascular effects seem attenuated when the particulate portion is removed. We would like to know if that is true for respiratory and immunological endpoints. Understanding these changes may help us prevent health problems associated with air pollution in the future.

  1. Research Method:

Blinded crossover experiment between four conditions (DE and allergen, PDDE and allergen, FA and allergen, FA and saline), randomized and counter-balanced to order. Each condition will be separated by a 4-week washout period.

An inhaled allergen or saline challenge is delivered after each exposure (DE, PDDE, or FA). 24 h post challenge, airway reactivity will be assessed with a methacholine challenge. 48 h post challenge, bronchoalveolar lavage (BAL), airway brushes and tissue biopsies will be obtained for analysis of immune activation. Nasal lavage samples will also be collected to examine responses in the upper airways and blood and urine will be studied to examine systemic responses. Spirometry and methacholine challenge will be used to assess effects on airway function.

Study Design

Study Type:
Interventional
Actual Enrollment :
13 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Strengthening the Case for Ongoing Reduction of Exposure to Traffic-Related Air Pollution
Actual Study Start Date :
Jan 1, 2014
Actual Primary Completion Date :
Apr 1, 2017
Actual Study Completion Date :
Apr 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Filtered air

Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge

Other: Allergen
Subject specific allergen is inhaled on day 1 of the triad

Experimental: Diesel exhaust

Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge

Other: Allergen
Subject specific allergen is inhaled on day 1 of the triad

Active Comparator: Filtered air control

Exposure for 2 hours to filtered air followed by inhaled saline challenge

Other: Saline
Saline is inhaled on day 1 of the triad

Experimental: Particle depleted diesel exhaust

Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge

Other: Allergen
Subject specific allergen is inhaled on day 1 of the triad

Other: Particle depleted diesel exhaust
High-efficiency particulate filtration of diesel exhaust

Outcome Measures

Primary Outcome Measures

  1. Immune response to allergen +/- DE (BAL) [48 hours]

    BAL cellular differential and activation,

  2. Immune response to allergen +/- DE (Th1/Th2/IgE/IgG4) [48 hours]

    Th1/Th2 profile and IgE and IgG4 specific to the allergen used for allergen challenge will be assessed.

Secondary Outcome Measures

  1. Epithelial cell DNA methylation [48 hours]

    Determine if allergen-induced changes in DNA methylation within epithelial cells is augmented by DE (300 µg/m3 inhaled for two hours) and attenuated by PDDE.

  2. Proteomic signature [48 hours]

    Determine if allergen-induced changes in proteomic profile within epithelial cells is augmented by DE (300 µg/m3 inhaled for two hours) and attenuated by PDDE.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 49 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age between 19 and 49 years

  • Non-smoking

  • Positive skin prick test for at least one of: birch, grass, or dust

Exclusion Criteria:
  • Using inhaled corticosteroids

  • Pregnant or planning to be pregnant in the next 12 months / Breastfeeding

  • Usage of bronchodilators more than three times per week.

  • Co-morbidities (as assessed by the primary investigator)

  • Taking part in other studies

  • Unwilling to withhold bronchodilator, aspirin, anti-coagulant, antihistamine or decongestant medications or caffeine prior to testing procedures.

  • FEV1(Forced expiratory volume in one second) < 70% predicted.

  • Allergy to lidocaine, fentanyl, midazolam or salbutamol.

  • Unstable asthma (i.e exacerbation in 2 weeks preceding testing)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of British Columbia Vancouver British Columbia Canada V5Z 1M9

Sponsors and Collaborators

  • University of British Columbia

Investigators

  • Principal Investigator: Christopher Carlsten, MD, MPH, University of British Columbia

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Christopher Carlsten, Principal Investigator, University of British Columbia
ClinicalTrials.gov Identifier:
NCT02017431
Other Study ID Numbers:
  • H11-01831/2013
First Posted:
Dec 20, 2013
Last Update Posted:
Sep 29, 2017
Last Verified:
Sep 1, 2017
Keywords provided by Christopher Carlsten, Principal Investigator, University of British Columbia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 29, 2017